Jazz Pharmaceuticals (NASDAQ:JAZZ) Upgraded to “Strong-Buy” by StockNews.com

StockNews.com upgraded shares of Jazz Pharmaceuticals (NASDAQ:JAZZGet Rating) from a buy rating to a strong-buy rating in a research report report published on Monday.

A number of other equities research analysts also recently issued reports on the stock. Needham & Company LLC reduced their price target on shares of Jazz Pharmaceuticals from $210.00 to $208.00 and set a buy rating on the stock in a research note on Thursday, November 10th. SVB Leerink boosted their price target on shares of Jazz Pharmaceuticals from $200.00 to $210.00 and gave the company an outperform rating in a research note on Thursday, August 4th. BMO Capital Markets boosted their price target on shares of Jazz Pharmaceuticals from $185.00 to $188.00 and gave the company an outperform rating in a research note on Thursday, August 4th. UBS Group cut their target price on shares of Jazz Pharmaceuticals from $194.00 to $191.00 and set a buy rating on the stock in a research note on Thursday, August 4th. Finally, The Goldman Sachs Group upped their target price on shares of Jazz Pharmaceuticals from $170.00 to $192.00 and gave the stock a neutral rating in a research note on Thursday, November 10th. Two investment analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of Moderate Buy and a consensus target price of $202.50.

Jazz Pharmaceuticals Stock Performance

NASDAQ:JAZZ opened at $148.86 on Monday. The company has a debt-to-equity ratio of 2.07, a current ratio of 3.16 and a quick ratio of 2.27. The firm has a market capitalization of $9.37 billion, a price-to-earnings ratio of -496.20, a PEG ratio of 0.88 and a beta of 0.74. The company’s 50-day moving average is $139.53 and its two-hundred day moving average is $148.14. Jazz Pharmaceuticals has a 1-year low of $117.64 and a 1-year high of $169.98.

Insider Transactions at Jazz Pharmaceuticals

In other news, SVP Finbar Larkin sold 197 shares of the firm’s stock in a transaction on Monday, November 14th. The shares were sold at an average price of $149.33, for a total value of $29,418.01. Following the completion of the sale, the senior vice president now owns 19,409 shares in the company, valued at approximately $2,898,345.97. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, SVP Finbar Larkin sold 197 shares of the stock in a transaction dated Monday, November 14th. The shares were sold at an average price of $149.33, for a total value of $29,418.01. Following the completion of the transaction, the senior vice president now owns 19,409 shares in the company, valued at approximately $2,898,345.97. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Bruce C. Cozadd sold 7,703 shares of the firm’s stock in a transaction dated Tuesday, September 6th. The shares were sold at an average price of $153.18, for a total transaction of $1,179,945.54. Following the transaction, the chief executive officer now owns 353,311 shares of the company’s stock, valued at $54,120,178.98. The disclosure for this sale can be found here. In the last quarter, insiders sold 56,211 shares of company stock worth $7,780,391. Company insiders own 4.40% of the company’s stock.

Institutional Trading of Jazz Pharmaceuticals

A number of hedge funds have recently made changes to their positions in the company. Trustcore Financial Services LLC increased its stake in shares of Jazz Pharmaceuticals by 47.7% in the first quarter. Trustcore Financial Services LLC now owns 347 shares of the specialty pharmaceutical company’s stock worth $54,000 after buying an additional 112 shares during the last quarter. Asset Management One Co. Ltd. lifted its holdings in Jazz Pharmaceuticals by 4.6% in the second quarter. Asset Management One Co. Ltd. now owns 25,460 shares of the specialty pharmaceutical company’s stock worth $3,972,000 after purchasing an additional 1,112 shares during the period. Keybank National Association OH acquired a new stake in Jazz Pharmaceuticals in the second quarter worth about $1,572,000. Brighton Jones LLC acquired a new stake in Jazz Pharmaceuticals in the second quarter worth about $202,000. Finally, Exchange Traded Concepts LLC raised its position in Jazz Pharmaceuticals by 9.2% in the second quarter. Exchange Traded Concepts LLC now owns 4,786 shares of the specialty pharmaceutical company’s stock worth $747,000 after acquiring an additional 402 shares in the last quarter. Hedge funds and other institutional investors own 92.79% of the company’s stock.

About Jazz Pharmaceuticals

(Get Rating)

Jazz Pharmaceuticals Plc operates as a biopharmaceutical company, which focuses on the identification, development and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain and psychiatry. Its product portfolio includes: Xyrem, Xywav, Sunosi, Erwinaze, Vyxeos, Defitelio, and Zepzelca.

Further Reading

Analyst Recommendations for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.